In the Treatment Options Preservation Study (TOPS) trial, 4 or 7 days of Combivir (CBV; zidovudine/ lamivudine) with maternal single-dose nevirapine (sdNVP) significantly reduced the emergence of NVP resistance as determined by virus population genotyping. To detect NVP resistance with greater sensitivity, we analysed TOPS samples by allele-specific real-time PCR (ASP).
Methods
In a random subset of women from each arm of the trial, plasma samples from before and 6 weeks after sdNVP were analysed using ASP at codons 103, 181, 184 and 190.
Results
Samples were analysed from 27 women in the sdNVP arm and 24 each in the CBV 4-day (sdNVP/ CBV4) and 7-day (sdNVP/CBV7) arms. ASP detected NVP-resistant variants in week 6 samples from 70% of women in the sdNVP arm, 29% in the sdNVP/CBV4 arm and 33% in sdNVP/CBV7 arm (P<0.01 for sdNVP/CBV4 or sdNVP/ CBV7 versus sdNVP; P=1.0 for sdNVP/CBV4 versus sdNVP/ CBV7). Lamivudine resistance was detected by ASP in only 1 of 51 women who received CBV.
Conclusions
Short-course CBV significantly reduced but did not eliminate the emergence of NVP resistance after sdNVP. NVP-resistant variants were detected in about one-third of women despite CBV treatment, but the duration of persistence and clinical impact of these variants in response to antiretroviral therapy is uncertain.
References
1.
GuayL.A., MusokeP., FlemingT.Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet1999; 354: 795–802.
2.
JacksonJ.B., MusokeP., FlemingT.Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet2003; 362: 859–868.
3.
ArrivéE., DabisF.Prophylactic antiretroviral regimens for prevention of mother-to-child transmission of HIV in resource-limited settings. Curr Opin HIV AIDS2008; 3: 161–165.
4.
EshlemanS.H., MracnaM., GuayL.A.Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS2001; 15: 1951–1957.
5.
FlysT., NissleyD.V., ClaasenC.W.Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. J Infect Dis2005; 192: 24–29.
6.
JohnsonJ.A., LiJ.F., MorrisL.Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J Infect Dis2005; 192: 16–23.
7.
PalmerS., BoltzV., MartinsonN.Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission. Proc Natl Acad Sci U S A2006; 103: 7094–7099.
8.
MartinsonN.A., MorrisL., GrayG.Selection and persistence of viral resistance in HIV-infected children after exposure to single-dose nevirapine. J Acquir Immune Defic Syndr2007; 44: 148–153.
9.
FlysT.S., DonnellD., MwathaA.Persistence of K103N-containing HIV-1 variants after single-dose nevirapine for prevention of HIV-1 mother-to-child transmission. J Infect Dis2007; 195: 711–715.
10.
JourdainG., Ngo-Giang-HuongN., Le CoeurS.Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med2004; 351: 229–240.
11.
CoovadiaA., HuntG., AbramsE.J.Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy. Clin Infect Dis2009; 48: 462–472.
12.
LockmanS., HughesM., McIntyreJ.Lopinavir/ ritonavir versus nevirapine-based antiretroviral therapy in women with and without prior single-dose nevirapine use. N Engl J Med2010; 363: 1499–1509.
13.
BoltzV.F., ZhengY., LockmanS.Role of low-frequency HIV-1 variants in failure of nevirapine-containing antiviral therapy in women previously exposed to single-dose nevirapine. Proc Natl Acad Sci U S A2011; 108: 9202–9207.
14.
McIntyreJ.A., HopleyM., MoodleyD.Efficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of mother-to-child HIV transmission: a randomized clinical trial. PLoS Med2009; 6: e1000172.
15.
World Health Organization. Antiretroviral drugs for treating pregnant women and preventing HIV infections in infants. Recommendations for a public health approach. Geneva: World Health Organization2010.
16.
HalvasE.K., AldrovandiG.M., BalfeP.Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency. J Clin Microbiol2006; 44: 2612–2614.
17.
PalmerS., BoltzV., MaldarelliF.Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy. AIDS2006; 20: 701–710.
18.
BoltzV.F., MaldarelliF., MartinsonN.Optimization of allele-specific PCR using patient-specific HIV consensus sequences for primer design. J Virol Methods2010; 164: 122–126.
19.
PalmerS., KearneyM., MaldarelliF.Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J Clin Microbiol2005; 43: 406–413.
20.
KearneyM., PalmerS., MaldarelliF.Frequent polymorphism at drug resistance sites in HIV-1 protease and reverse transcriptase. AIDS2008; 22: 497–501.
21.
GiffordR.J., LiuT.F., RheeS.Y.The calibrated population resistance tool: standardized genotypic estimation of transmitted HIV-1 drug resistance. Bioinformatics2009; 25: 1197–1198.
22.
JohnsonJ.A., LiJ.F., WeiX.Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLoS Med2008; 5: e158.
ParedesR., LalamaC.M., RibaudoH.J.Preexisting minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. J Infect Dis2010; 201: 662–671.
25.
HalvasE.K., WiegandA., BoltzV.F.Low frequency nonnucleoside reverse transcriptase inhibitor–resistant variants contribute to failure of efavirenz-containing regimens in treatment-experienced patients. J Infect Dis2010; 201: 672–680.
26.
HeneineW.When do minority drug-resistant HIV-1 variants have a major clinical impact?J Infect Dis2010; 201: 647–649.
27.
FarrS.L., NelsonJ.A.E., Ng'ombeT.J.Addition of 7 days of zidovudine plus lamivudine to peripartum single-dose nevirapine effectively reduces nevirapine resistance postpartum in HIV-infected mothers in Malawi. J Acquir Immune Defic Syndr2010; 54: 515–523.
28.
LockmanS., ShapiroR.L., SmeatonL.M.Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med2007; 356: 135–147.
29.
RowleyC.F., BoutwellC.L., LeeE.J.Ultrasensitive detection of minor drug-resistant variants for HIV after nevirapine exposure using allele-specific PCR: clinical significance. AIDS Res Hum Retroviruses2010; 26: 293–300.
